Drugs / LIPO-102
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00918606 | Feb → Jun 2009 | lipodystrophy | Neothetics, Inc | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01180465 | Apr → Sep 2010 | — | Neothetics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01096979 | Oct 2009 → Mar 2010 | abdominal obesity-metabolic syndrome | Neothetics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00954057 | Sep 2009 → Jun 2011 | disease of orbital part of eye adnexa | Neothetics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00918814 | Jun 2009 → Feb 2010 | lipodystrophy | Neothetics, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIPO-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00918606 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT00918814 ↗ |